Wahlstrom Mats

CIK 00014591543 companiesGOLDEN, CO

SEC Profile

Transactions

Companies

Filings

CIK

0001459154

Recent Transactions

50 trades

Award
TriSalus Life Sciences, Inc.$TLSI
Director Stock Option (right to buy)
2025-06-12+15,000→ 200,945 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2025-06-12+112,000→ 112,000 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock
2025-05-23$0.74/sh−99,988→ 0 total
Other
TriSalus Life Sciences, Inc.$TLSI
Series A Convertible Preferred Stock
2025-02-10+44,750→ 94,750 total
Award
TriSalus Life Sciences, Inc.$TLSI
Common Stock
2024-12-17$3.97/sh+25,188→ 40,915 total
Purchase
TriSalus Life Sciences, Inc.$TLSI
Common Stock
2024-11-22$4.55/sh+5,000→ 15,727 total
Purchase
TriSalus Life Sciences, Inc.$TLSI
Common Stock
2024-11-21$4.44/sh+8,687→ 10,727 total
Purchase
TriSalus Life Sciences, Inc.$TLSI
Common Stock
2024-11-20$4.16/sh+2,040→ 2,040 total
Award
TriSalus Life Sciences, Inc.$TLSI
Director stock option (right to buy)
2024-08-13+15,000→ 15,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2024-06-03+112,000→ 112,000 total
Gift
Coherus Oncology, Inc.$CHRS
Common Stock
2024-02-09+99,988→ 99,988 total
Gift
Coherus Oncology, Inc.$CHRS
Common Stock
2024-02-09−99,988→ 0 total
Exercise/Conversion
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2024-02-01−14,997→ 0 total
Exercise/Conversion
Coherus Oncology, Inc.$CHRS
Common Stock
2024-02-01$1.67/sh+44,991→ 99,988 total
Exercise/Conversion
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2024-02-01−44,991→ 0 total
Exercise/Conversion
Coherus Oncology, Inc.$CHRS
Common Stock
2024-02-01$1.67/sh+14,997→ 54,997 total
Award
TriSalus Life Sciences, Inc.$TLSI
Stock Option (right to buy)
2023-08-10+35,000→ 35,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2023-06-07+38,250→ 38,250 total
Award
Coherus Oncology, Inc.$CHRS
Common Stock
2022-02-28$2.08/sh+29,994→ 40,000 total
Exercise/Conversion
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2022-02-28+29,994→ 0 total
Award
Coherus Oncology, Inc.$CHRS
Common Stock
2022-02-25$11.64/sh+10,006→ 10,006 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2022-01-07+27,000→ 27,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2022-01-07+27,000→ 27,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2021-01-11+20,000→ 20,000 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2020-06-17$17.15/sh−200,000→ 0 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2020-03-03$20.09/sh−113,844→ 204,222 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2020-03-03$20.89/sh−4,222→ 200,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2020-01-10+20,000→ 20,000 total
Other
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2019-05-31−178,528→ 0 total
Other
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2019-05-31+98,152→ 318,066 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2019-01-11+20,000→ 20,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2018-02-01+20,000→ 20,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2017-05-17+20,000→ 20,000 total
Other
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2017-05-09−200,000→ 178,528 total
Other
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2017-05-09+109,957→ 219,914 total
Other
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2017-02-22−200,000→ 378,528 total
Other
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2017-02-22+109,957→ 109,957 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2016-12-08$27.52/sh−46,190→ 0 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2016-12-07$27.50/sh−7,393→ 46,190 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2016-05-24+10,000→ 10,000 total
Purchase
Coherus Oncology, Inc.$CHRS
8.2% Senior Convertible Notes due 2022
2016-02-29$22.35/sh+1,000,000→ 1,000,000 total
Purchase
Coherus Oncology, Inc.$CHRS
8.2% Senior Convertible Notes due 2022
2016-02-29$22.35/sh
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2015-08-18$33.50/sh−6,372→ 578,528 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2015-08-18$33.50/sh−6,373→ 578,527 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2015-08-17$33.91/sh−8,028→ 584,900 total
Sale
Coherus Oncology, Inc.$CHRS
Common Stock, $0.0001 par value
2015-08-14$34.24/sh−116,554→ 592,928 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2015-04-01+20,000→ 20,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2015-04-01+75,000→ 75,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2015-04-01+20,000→ 20,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2015-04-01+75,000→ 75,000 total

Companies

Recent Filings

Address

500 GOLDEN RIDGE ROAD, SUITE 100

GOLDEN, CO, 80401

View on SEC.gov